Achieve Life Sciences, INC Form 4 insider transactions

Achieve Life Sciences, Inc. Director Bridget A. Martell was granted 31,500 stock options with an exercise price of $3.83, vesting by June 2026.

Achieve Life Sciences, Inc. has reported that Director Thomas Braxton King was granted 31,500 stock options with an exercise price of $3.83 per share, vesting in 2026.

ACHIEVE LIFE SCIENCES, INC. Director Stuart Duty was granted 31,500 stock options with an exercise price of $3.83, vesting by June 2026.

Chief Financial Officer of Achieve Life Sciences, Mark Oki, reports the purchase of 10,000 shares of common stock.

Richard Alistair Stewart, CEO of Achieve Life Sciences, purchased 10,000 shares of common stock on March 17, 2025.

Jerry Wan, Principal Accounting Officer of Achieve Life Sciences, was granted 48,000 Performance Restricted Stock Units (PRSUs) on January 28, 2025, according to a Form 4 filing.

Jaime Xinos, Chief Commercial Officer of Achieve Life Sciences, was granted 100,000 performance-based restricted stock units (PRSUs) on January 28, 2025.

Cindy Jacobs, President & CMO of Achieve Life Sciences, was granted 130,000 Performance Restricted Stock Units (PRSUs) on January 28, 2025, according to a Form 4 filing.

Director Kristen B. Slaoui of Achieve Life Sciences acquired stock options for 47,250 shares on January 13, 2025.

Director Nancy R. Phelan of Achieve Life Sciences, Inc. was granted stock options to purchase 47,250 shares of common stock.

Achieve Life Sciences CEO, Richard Alistair Stewart, was granted 157,500 performance restricted stock units and 67,500 stock options on January 13, 2025.

Thomas Braxton King, Executive Chairman of Achieve Life Sciences, was granted 455,000 performance-restricted stock units and 195,000 stock options on January 13, 2025.

Jaime Xinos, Chief Commercial Officer of Achieve Life Sciences, was granted 20,000 stock options on January 13, 2025.

Jaime Xinos, Chief Commercial Officer of Achieve Life Sciences, was granted 30,000 stock options on December 6, 2024.

Achieve Life Sciences' Chief Financial Officer, Mark Oki, has acquired 72,000 stock options and 168,000 performance-based restricted stock units.

Jerry Wan, Principal Accounting Officer of Achieve Life Sciences, acquired 2,857 shares of common stock at $3.67 per share under the company's Employee Stock Purchase Plan on August 16, 2024.

Cindy Jacobs, President & CMO and Director of Achieve Life Sciences, acquired 2,660 shares of common stock through the company's Employee Stock Purchase Plan on August 16, 2024.

CEO John Bencich increased his holdings in Achieve Life Sciences by acquiring 5,000 shares of common stock through the company's Employee Stock Purchase Plan.

Jerry Wan, Principal Accounting Officer of Achieve Life Sciences, reports the acquisition and disposal of common stock related to the settlement of performance restricted stock units (PRSUs).

Cindy Jacobs, President & CMO of Achieve Life Sciences, reports the acquisition of 16,250 shares of common stock upon settlement of performance restricted stock units and the disposal of 3,957 shares to cover tax liabilities.

Richard Stewart, Executive Chairman of Achieve Life Sciences, reports the acquisition of 22,500 shares of common stock upon settlement of performance restricted stock units and the disposal of 10,125 shares to cover tax liabilities.

CEO John Bencich reports acquisition of 25,000 shares of Achieve Life Sciences common stock upon settlement of performance restricted stock units and disposition of 6,088 shares for tax liability.

Richard Stewart, Executive Chairman of Achieve Life Sciences, purchased 10,000 shares of common stock and warrants in a registered direct offering.

Achieve Life Sciences CEO John Bencich purchased 10,000 shares of common stock and warrants in a registered direct offering.